Robert Clark Brown, MD, PhD, Children’s Healthcare of Atlanta, Atlanta, GA, gives an update on a randomized Phase I study (NCT03815695) of FT-4202 versus placebo in patients with sickle cell disease (SCD). FT-4202 is a small molecule activator of erythrocyte pyruvate kinase (PKR), which acts to decrease 2,3-DPG and increase ATP in red blood cells. This Phase I study aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of FT-4202 in healthy volunteers and patients with SCD. Treatment-related adverse events to FT-4202 included nausea and headache. All adverse events in patients treated with FT-4202 were less than or equal to grade two. Dr Brown reports that of eight patients enrolled on the 8-week open-label extension, 7/8 have reached the target of increasing their hemoglobin to greater than 1g per dL, with a mean increase of 1.5g per dL above baseline. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.